In 2010, lapatinib was approved for use with an aromatase inhibitor (letrozole) in the treatment of post-menopausal women with metastatic BC co-expressing hormonal receptors (estrogen receptor (ER) and progesterone receptor (PR)) and HER2 [34, 36]. Here, CYP19A1 is linked to breast cancer.